Notably, a study by Leidner et al. demonstrated that TCRs targeting mutant KRAS (KRAS12D) elicited responses in one patient with metastatic PDAC, highlighting the potential of TCR-based therapies in this challenging cancer type [106]. The gene discussed is KRAS; the disease is cancer.